Home/Pipeline/M9140

M9140

Colorectal Cancer

Phase 1/2Active

Key Facts

Indication

Colorectal Cancer

Phase

Phase 1/2

Status

Active

Company

Merck KGaA

About Merck KGaA

Merck KGaA's mission is to advance science and technology to improve lives and solve pressing challenges. Its key achievements include building a leading oncology franchise with Bavencio, establishing MilliporeSigma as a dominant global supplier to the life science industry, and becoming a critical materials partner for the electronics sector. The company's strategy leverages its deep scientific expertise across its three interconnected pillars to capitalize on long-term trends in healthcare digitization, biopharma outsourcing, and technological miniaturization.

View full company profile

Therapeutic Areas

Oncology Neurology Immunology

Other Colorectal Cancer Drugs

Drug	Company	Phase	Status
CY-101 + Pembrolizumab	Cytovation	Phase 1/2	Initiate 1H-26
Repositioned/Rerouted API	Reponex	Not Specified	Active
Leronlimab	CytoDyn	Phase 2	Phase in progress
EGFR inhibitor	Acellera	Pre-clinical	Hit Identification
Cannabics® RCC-33	CNBX Pharmaceuticals	Preclinical	Preparation of Pre-IND Meeting Package
VCR-036	Vicero Bio	Preclinical	Active
CBI-1214	Cartography Biosciences	Phase 1	Active
QL335	QLSF Biotherapeutics	Phase 1	Active
Colorectal Cancer Detection Partnership	Daisy Genomics	Research/Assay Development	Active
High Internalization ADC	Lytica Therapeutics	Preclinical	Active
Undisclosed Colorectal Program(s)	Tavanta Therapeutics	Phase 2	Active
KRAS AK™PCR Mutation Screen Kit	Akcell Biotech	Commercial	Active